Skip to main content

Table 1 Demographics of study populations for WES and WTS analysis

From: Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma

  All (n = 65) WES (n = 58) WTS (n = 48)
Sex, no. (%)    
 Male 30 (46.2) 25 (43.1) 25 (52.1)
 Female 35 (53.8) 33 (56.9) 23 (47.9)
Age, median years (range) 3.1 (0–14.9) 3.35 (0–14.9) 2.7 (0–10)
Age, no. (%)    
 < 18 months 18 (27.7) 11 (19.0) 16 (33.3)
 ≥ 18 months 47 (72.3) 47 (81.0) 32 (66.7)
Stage, no. (%)    
 Localized 30 (46.2) 27 (46.6) 24 (50.0)
 Metastatic 35 (53.8) 31 (53.4) 24 (50.0)
Risk group, no. (%)    
 High-risk 26 (40.0) 26 (44.8) 16 (33.3)
 Non-high risk 39 (60.0) 32 (55.2) 32 (66.7)
Pathology, no. (%)    
 Undifferentiated 1 (1.5) 1 (1.7) 1 (2.1)
 Poorly differentiated 25 (38.5) 21 (36.2) 19 (39.6)
 Differentiating 13 (20.0) 11 (19.0) 9 (18.8)
 Ganglioneuroblastoma (GNB) 26 (40.0) 25 (43.1) 19 (39.6)